Ameriprise Financial Inc. Has $3.09 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Ameriprise Financial Inc. trimmed its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 178,904 shares of the company's stock after selling 25,817 shares during the period. Ameriprise Financial Inc. owned approximately 0.21% of Progyny worth $3,086,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Signaturefd LLC boosted its position in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after purchasing an additional 1,355 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares during the period. Caitlin John LLC grew its stake in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after buying an additional 3,183 shares in the last quarter. Natixis purchased a new stake in shares of Progyny during the 4th quarter valued at about $69,000. Finally, SBI Securities Co. Ltd. acquired a new position in Progyny during the 4th quarter worth approximately $74,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on PGNY. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research report on Monday, March 31st. Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group dropped their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Progyny currently has a consensus rating of "Hold" and an average target price of $23.45.

Progyny Trading Up 0.4%

PGNY traded up $0.09 during midday trading on Thursday, reaching $21.34. The company's stock had a trading volume of 1,069,810 shares, compared to its average volume of 1,706,396. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $30.42. The stock has a market cap of $1.83 billion, a P/E ratio of 36.79, a PEG ratio of 2.39 and a beta of 1.37. The company has a fifty day simple moving average of $22.10 and a 200 day simple moving average of $20.02.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same period in the previous year, the firm earned $0.17 EPS. The business's revenue was up 16.5% compared to the same quarter last year. Sell-side analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.